OpenEvidence, a instrument that docs and nurses have likened to ChatGPT for drugs, plans to announce a $200 million elevate at a $6 billion valuation, The New York Occasions studies.
The recent funds come three months after the startup raised a $210 million spherical at a $3.5 billion valuation, a testomony to the extraordinary investor curiosity in industry-specific AI purposes.
Skilled on medical journals from JAMA and the New England Journal of Drugs, the OpenEvidence platform helps customers rapidly get solutions to current medical data to assist deal with sufferers. Verified medical professionals can entry OpenEvidence’s instrument, which is supported by promoting, without spending a dime.
OpenEvidence has grown rapidly since its founding in 2022. Its variety of scientific consultations monthly has practically doubled to fifteen million since July, per the Occasions.
The spherical was led by Google Ventures, with participation from Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Administration, Bond, and Craft.
TechCrunch has reached out to OpenEvidence for remark.
Techcrunch occasion
San Francisco
|
October 27-29, 2025
{content material}
Supply: {feed_title}